BPC 157 is a synthetically derived pentadecapeptide modeled after a protective protein fragment native to human gastric juice. This technical reference details the complete bpc 157 chemical structure, primary amino acid sequence, molecular weight, and analytical validation metrics required for rigorous in vitro and preclinical research applications.
BPC 157 is a synthetically derived pentadecapeptide modeled after a protective protein fragment native to human gastric juice. This technical reference details the complete bpc 157 chemical structure, primary amino acid sequence, molecular weight, and analytical validation metrics required for rigorous in vitro and preclinical research applications.
The bpc 157 chemical structure represents a synthetic pentadecapeptide comprising 15 amino acids arranged in the specific primary sequence: L-Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolyl-L-glycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanyl-L-glycyl-L-leucyl-L-valine (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). Its molecular formula is C62H98N16O22, yielding an exact monoisotopic mass of 1418.70 atomic mass units (Da) and a average molecular weight of approximately 1419.53 g/mol.
Unlike many naturally occurring signaling peptides, the BPC-157 peptide chain lacks internal disulfide bridges, relying instead on a high proportion of proline residues to maintain conformational stability. The presence of a rigid proline-triplet cluster (Pro-Pro-Pro) near the N-terminus imparts significant structural resistance against enzymatic cleavage by endopeptidases. This structural resilience allows researchers to evaluate the compound in diverse assay environments, including acidic or proteolytically demanding in vitro conditions.
To fully understand the structural chemistry of BPC-157, researchers analyze the peptide sequence from its N-terminus to its C-terminus. The peptide opens with an uncharged glycine residue followed by an acidic glutamic acid residue, establishing an amphipathic N-terminal domain. Immediately following is a sequence of three consecutive proline residues (Pro3-Pro4-Pro5), which imposes steric constraints and forces a distinct polyproline II helical backbone fragment. This conformational restriction is critical for its receptor interaction profiles observed in bench scientific models.
The middle region of the peptide sequence features a basic lysine residue flanked by glycine and proline (Gly6-Lys7-Pro8), contributing localized positive charge density at physiological pH. The C-terminal region contains two consecutive aspartic acid residues (Asp10-Asp11) providing negative electrostatic charge, followed by hydrophobic alanine, glycine, leucine, and valine residues. This balanced distribution of charged, polar, and non-polar amino acid side chains yields a highly soluble, stable peptide suitable for quantitative liquid formulations in bench research.
The primary physicochemical characteristic of BPC-157 is its unusual enzymatic and thermal stability relative to standard linear peptides. Standard synthetic peptides lacking disulfide bonds frequently undergo rapid enzymatic degradation when exposed to biological matrices. However, physical modeling and spectroscopic assays demonstrate that the proline-dense regions within the BPC 157 chemical structure protect the peptide backbone from rapid hydrolysis.
In solution, BPC-157 exhibits an isoelectric point (pI) determined by the balance of its acidic side chains (glutamic acid and two aspartic acid residues) and basic side chain (lysine). At neutral pH (7.4), the net charge of the molecule is negative (-2), promoting high aqueous solubility in standard laboratory buffers such as Phosphate-Buffered Saline (PBS). This solubility profile facilitates consistent preparation for cellular migration assays, receptor binding experiments, and tissue culture studies documented across the research library hub.
In vitro and animal models show that the unique structural arrangement of BPC-157 correlates with specific cellular signaling cascades related to tissue repair. Preclinical studies suggest that the compound accelerates repair processes in tendon, ligament, skeletal muscle, and gut lining tissues through the modulation of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) signaling pathways.
Observation of endothelial cell cultures indicates that BPC-157 promotes early angiogenesis—the formation of new blood vessels from existing vascular networks—by stimulating VEGFR2 phosphorylation and activating the focal adhesion kinase (FAK)-paxillin pathway. This mechanism drives cellular migration and capillary sprouting to injured tissue sites without inducing uncontrolled cell proliferation. Further details on structural activation mechanics can be reviewed in our analysis of BPC-157 mechanisms of action.
When evaluating structural features of tissue repair peptides, investigators frequently compare BPC-157 to other regulatory molecules such as TB-500 (a synthetic fragment of Thymosin Beta-4) and GHK-Cu (a copper-binding tripeptide). While BPC-157 operates as a 15-amino-acid pentadecapeptide targeting VEGFR2 activation and FAK-paxillin pathway signaling, TB-500 utilizes an actin-binding domain (LKKTETQ motif) to promote cell motility and actin polymerization.
In contrast, GHK-Cu relies on a small tripeptide structure (Gly-His-Lys) coordinated with a divalent copper ion ($Cu^{2+}$) to modulate extracellular matrix remodeling and gene expression. Understanding these structure-activity relationships (SAR) allows laboratory investigators to select the precise peptide architecture necessary for specific signaling pathways or cellular repair models. Researchers exploring multiple repair pathways can view PX1's comprehensive research catalog for analytical comparison.
Validating the structural identity and purity of synthesized BPC-157 requires rigorous physical-chemical testing. Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) is used to establish chemical purity, ensuring that the isolated peptide peak accounts for $\ge 99\%$ of total integrated chromatogram area, free from deletion sequences or incomplete synthesis byproducts.
Complementing HPLC, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular weight by verifying the primary single protonated molecular ion $[M+H]^+$ at $m/z \approx 1419.53$. In addition to mass and purity verification, every research lot supplied by PX1 Research undergoes kinetic chromogenic LAL assays to ensure endotoxin levels remain below strict laboratory limits ($< 0.01\text{ EU/mg}$). Each order includes a lot-specific Certificate of Analysis (COA) generated by independent ISO 17025 accredited laboratories.
For quantitative laboratory experimentation, BPC-157 lyophilized powder must be reconstituted using proper aseptic techniques and appropriate solvent systems. Standard laboratory diluents include sterile 0.9% sodium chloride (normal saline), phosphate-buffered saline (PBS, pH 7.4), or sterile bacteriostatic water containing 0.9% benzyl alcohol depending on the planned assay timeline.
When preparing solutions, laboratory personnel should introduce the diluent down the inner wall of the glass vial to prevent excessive shear stress on the peptide cake. Gentle swirling is recommended; mechanical vortexing should be avoided as it can introduce air bubbles and induce conformational denaturation at the liquid-air interface. Comprehensive protocol details are accessible via the PX1 peptide reconstitution guide.
Lyophilized BPC-157 exhibits high stability when stored at sub-zero temperatures. For long-term storage, unopened vials containing dry peptide powder should be maintained at $-20^\circ\text{C}$ to $-80^\circ\text{C}$, protected from light exposure and atmospheric moisture. Under these conditions, the structural integrity of the peptide remains stable for up to 24 months without measurable degradation.
Once reconstituted into aqueous solution, peptide stability decreases over time due to potential hydrolysis and oxidation processes. Reconstituted solutions should be kept refrigerated at $2^\circ\text{C}$ to $8^\circ\text{C}$ and utilized within 30 days. Multiple freeze-thaw cycles must be avoided to prevent ice crystal formation that can disrupt the primary peptide backbone structure. For extended liquid stability parameters, refer to our peptide storage guidelines.
Reliable scientific outcomes depend directly on the purity, lot consistency, and structural integrity of research reagents. PX1 Research synthesizes all peptide compounds in state-of-the-art cGMP-compliant facilities located in the United States. Every lot is verified by independent, third-party testing laboratories to guarantee exact sequence identity, chemical purity exceeding $99\%$, and minimal endotoxin levels.
PX1 Research provides fast, reliable distribution with same-day shipping on orders placed Monday through Friday from centralized fulfillment hubs in California and Arizona. Scientific institutions and corporate research facilities requiring bulk quantities or dedicated analytical documentation can set up direct procurement accounts through the PX1 wholesale research portal.
What is the exact bpc 157 chemical structure?
The BPC 157 chemical structure is a 15-amino-acid synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its chemical formula is C62H98N16O22, with a molecular mass of approximately 1419.53 g/mol.
What is the molecular weight of BPC 157?
The monoisotopic molecular weight of BPC-157 is 1418.70 Da, with an average overall formula weight of 1419.53 g/mol, as verified by Mass Spectrometry (ESI-MS).
Does BPC 157 contain any disulfide bonds?
No, BPC 157 does not contain cysteine residues or internal disulfide bonds. Its structural stability is maintained by a rigid tri-proline cluster near the N-terminus.
How is BPC 157 purity verified by PX1 Research?
Every lot of BPC-157 undergoes Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity (>99%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm sequence identity and molecular weight.
What are the endotoxin limits for PX1 Research BPC 157?
PX1 Research tests every peptide batch for endotoxins using kinetic chromogenic LAL assays, guaranteeing levels fall strictly below < 0.01 EU/mg to prevent confounding cellular responses in experimental assays.
What solvents should be used for BPC 157 laboratory reconstitution?
For in vitro and preclinical research, BPC 157 is commonly reconstituted in sterile 0.9% sodium chloride solution, phosphate-buffered saline (PBS, pH 7.4), or sterile bacteriostatic water.
How should lyophilized BPC 157 powder be stored?
Unopened, lyophilized BPC 157 powder should be stored long-term at -20°C to -80°C in a desiccated environment protected from light exposure.
What biological pathways are targeted by BPC 157 in preclinical models?
In preclinical cellular models, BPC 157 targets the VEGFR2 pathway to induce endothelial cellular migration and early angiogenesis, alongside activation of the focal adhesion kinase (FAK)-paxillin signaling cascade.
How does BPC 157 differ structurally from TB-500?
BPC 157 is a 15-amino-acid gastric pentadecapeptide that acts primarily via VEGFR2 phosphorylation, whereas TB-500 is a 43-amino-acid synthetic peptide fragment of Thymosin Beta-4 containing an actin-binding motif (LKKTETQ) that sequester G-actin.
Where is PX1 Research BPC 157 manufactured and shipped from?
PX1 Research peptides are manufactured in GMP-compliant facilities within the USA and shipped same-day (Monday through Friday) directly from warehouse facilities in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.